of b-IFN. On the other hand, although a de novo leukaemia cannot be completely excluded, the pathogenetic link between the use of mitoxantrone and the development of secondary leukaemia was strongly supported in this case by the lack of concomitant potentially leukaemogenic treatments as well as by the morphologic and cytogenetic characteristics of leukaemia, the lack of myelodysplasia and the short latency period. Moreover, the evidence of early molecular relapse indicates a prognosis worse than that expected in APL patients treated with ATRA, a frequent characteristic of secondary neoplasms. We conclude that a note of caution may be suggested in the early use of this potentially dangerous agent in chronic nonmalignant diseases like MS.
Microdose a-interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report Leukemia (2003) 17, 986-987. doi:10.1038/sj.leu.2402904
TO THE EDITOR
Extramedullary myeloid tumors (EMMT) are peculiar neoplasms that derive from myeloid progenitors, onset as solid masses in different tissues, involving bone marrow and peripheral blood only at the latest stages of progression. 1 The prognosis is strictly related to a correct diagnosis and a prompt intervention with a fitting treatment. In fact, patients are curable when treated early with conventional regimens for acute myeloid leukemias (AML); unfortunately, however, the initial diagnosis is frequently not correct and the appropriate treatment is delayed, with subsequent unsatisfactory results. Bone marrow transplantation (BMT) is probably the only curative approach in lately diagnosed cases, but it is rarely suitable for the high toxicity; new strategies are thus warranted in order to improve the outcome. 1, 2 Increase of angiogenesis has been described in myeloproliferative disorders, such as AML and myelodysplastic syndromes (MDS), with clues to prognosis, [3] [4] [5] whereas no data are available in EMMT. Alpha-interferon (a-IFN) has been reported to be an antiangiogenic agent with clinical efficacy in a few cases of solid tumors. 6 In vitro data show that doses of IFN equivalent to thousand units in vivo are able to exert antiangiogenic activity, provided that a daily administration is effected. We thus studied the effects of an approach with microdoses of a-IFN in a young patient with EMMT refractory to salvage therapy after relapse, evaluating the effects produced on a surrogate angiogenesis marker.
In 1998, a 23-year-old man was diagnosed at another Institution for extranodal anaplastic large-cell lymphoma, localized at the ileopsoas muscle with involvement of the acetabulum and then treated with the progression of disease during the treatment. PBSC were then collected in order to perform an autologous bone marrow transplant (ABMT). The patient was then evaluated at our Institute and the histological diagnosis was reviewed and reformulated as compatible with EMMT. The patient thus received an ABMT conditioned with busulfan 4 mg/kg p.o. days À3 to À6 and melphalan 140 mg/m 2 i.v. day À2, a conditioning regimen effective in AML. No therapy has been proposed for reinduction of complete remission before ABMT, because of the high previous toxicity; in particular, left ventricular ejection resulted was poor (the ejection fraction was 40%). Local radiotherapy (2100 cGy fields) was then applied after recovery from ABMT. Unfortunately, the restaging performed 1.5 months after the end of radiotherapy showed a progression of the disease.
We thus administered to the patient a-IFN, at low doses (10.000 IU s.c./day) daily for 6 months. The angiogenesis parameters were studied at baseline, before starting a-IFN treatment. MVD resulted significantly increased in comparison with normal tissue and plasmatic basic fibroblast growth factor (bFGF), a surrogate angiogenesis parameter, was again increased if compared with normal parameters (Figure 1 ). The patient did not experience side effects during the treatment; his phisical conditions improved.
After the 6 months treatment period, a restaging was performed. Positron emission tomography (PET) and standard radiograms documented a good partial response, with disappearance of two out of three bone lesions.
Laboratory tests showed a concomitant clear reduction of plasmatic bFGF (Figure 1 Angiogenesis probably plays a significant role in hematological malignancies, and antiangiogenic therapies could be valuable in this setting. At this moment, clinical data are available only as regards thalidomide, an immunomodulatory agent with antiangiogenic properties and a spread of antitumor activities in multiple myeloma, MDS, AML and myelofibrosis with myeloid metaplasia. Antiangiogenic effects have been postulated for a wide range of biological modifiers, included a-IFN, in vitro.
We observed a clear clinical response, although temporary, to very low doses of a-IFN in our patient, with a concomitant reduction of a surrogate parameter of angiogenesis, bFGF. This is the first case, in our knowledge, of a hemopoietic malignancy successfully treated with microdoses of a-IFN, with, in addition, an evidence of antiangiogenic activity.
We conclude that an antiangiogenic approach with microdoses of a-IFN should be further studied in order to better define its role in the treatment of EMMT, in particular in frail cases temporarily or definitely excluded from standard or high-dose therapies, taking in account, in addition, the absolute absence of side effects. 
Extranodal NK/T-cell lymphoma, nasal type (NK-NHL), is a rare disease in North America and Europe, but is not uncommon in Asia and South America. This lymphoma is characterized by extranodal presentation, angiocentric and angiodestructive proliferation of cells including large granular lymphocytes, and rather characteristic pheno-and genotypes characterized by CD2+, CD3e + , surface CD3À, CD16À/+, CD56+, CD57À, and the absence of clonal rearrangements of T-cell receptor (TCR) genes. Clinically, localized NK-NHL is usually sensitive to radiation therapy. However, the prognosis is usually poor once dissemination occurs, and long-term remission even with aggressive chemotherapy is rare. At present, an elevated serum LDH level and the presence of B symptoms are known to be poor prognostic factors. We previously found that a differentiation inhibitory factor (I-factor) purified from a differentiation-resistant mouse myelogenous leukemia cell line was identical to nm23 protein. 1 Recently, we established an enzyme-linked immunosorbent assay (ELISA) technique of determining the serum level of nm23-H1 protein, 2 and reported that the level in patients with aggressive lymphoma was significantly higher than that in healthy individuals. Furthermore, this assay system can be useful to determine the therapeutic strategy for aggressive lymphoma since the prognosis is worse in patients with a high nm23-H1 level. In the present study, we report that the serum level of nm23-H1 was elevated in patients with NK-NHL, and that the level was significantly correlated with the clinical outcome. It is suggested by these findings that the serum level of nm23-H1 may be a valuable prognostic factor for patients with NK-NHL.
In all, 60 untreated NK-NHL patients who were consecutively enrolled and managed by the Adult Lymphoma Treatment Study Group (ALTSG) in Japan from 1988 to 2000 were the subject of the present study. The patients consisted of 31 males and 29 females with a median age of 49 years (range: 15-88 years). A brief summary Evaluation of plasmatic bFGF before and after treatment.
